🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the infection, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are increasing globally, with figures suggesting over 82 million infections annually. Especially elevated rates are reported in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options currently available.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Gain Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This approval represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

Based on findings detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The study enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have shared hope. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is deemed vital to alleviate the strain of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.